The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma
Open Access
- 29 January 2022
- journal article
- research article
- Published by Elsevier in Epilepsy & Behavior Reports
- Vol. 18, 100526
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- From molecules to medicines: the dawn of targeted therapies for genetic epilepsiesNature Reviews Neurology, 2018
- CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014Neuro-Oncology, 2017
- Mutant IDH1 and seizures in patients with gliomaNeurology, 2017
- An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsyJournal of Clinical Neuroscience, 2016
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Seizures in oligodendroglial tumorsCNS Oncology, 2015
- Clinical Management of Seizures in Patients With Low-Grade GliomaSeminars in Radiation Oncology, 2015
- Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic reviewNeuro-Oncology, 2015
- IDHMutation in GliomaJAMA Neurology, 2014
- Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomideJournal of Neurology, Neurosurgery & Psychiatry, 2014